2 weeks Ago By Defense World Staff
Immunocore ( NASDAQ:IMCR – Get Free Report ) was downgraded by equities researchers at Mizuho from an “outperform” rating to a “neutral” rating in a research report issued on Monday, Marketbeat.com reports. They currently have a $38.
00 price objective on the stock, down from their prior price objective of $72.00. Mizuho’s price objective indicates a potential upside of 12.
59% from the company’s previous close. A number of other analysts also recently issued reports on IMCR. UBS Group started coverage on shares of Immunocore in a report on Thursday, October 24th.
They set a “sell” rating and a $24.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $100.
00 price objective on shares of Immunocore in a report on Thursday, October 24th. Barclays decreased their price objective on Immunocore from $92.00 to $66.
00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $89.00 target price (up previously from $87.
00) on shares of Immunocore in a research note on Friday, August 9th. Finally, Needham & Company LLC decreased their price target on shares of Immunocore from $78.00 to $71.
00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.
com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $69.18. View Our Latest Stock Report on Immunocore Immunocore Price Performance Immunocore ( NASDAQ:IMCR – Get Free Report ) last posted its quarterly earnings data on Wednesday, November 6th.
The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.
50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.
84%. The company had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.
94 million. During the same period in the prior year, the business earned ($0.59) earnings per share.
Immunocore’s revenue for the quarter was up 23.7% compared to the same quarter last year. As a group, equities analysts anticipate that Immunocore will post -1.
11 EPS for the current fiscal year. Hedge Funds Weigh In On Immunocore Hedge funds have recently modified their holdings of the company. Exchange Traded Concepts LLC grew its stake in shares of Immunocore by 40.
4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after purchasing an additional 1,461 shares during the last quarter. Tidal Investments LLC purchased a new stake in Immunocore in the 1st quarter worth approximately $423,000.
Nan Fung Group Holdings Ltd bought a new stake in shares of Immunocore in the 1st quarter worth approximately $439,000. Connective Portfolio Management LLC purchased a new position in shares of Immunocore during the third quarter valued at approximately $218,000. Finally, DNB Asset Management AS raised its holdings in shares of Immunocore by 35.
0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after acquiring an additional 1,868 shares in the last quarter. Hedge funds and other institutional investors own 84.
50% of the company’s stock. About Immunocore ( Get Free Report ) Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. Read More Five stocks we like better than Immunocore What Are the U.K.
Market Holidays? How to Invest and Trade Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025 How to Calculate Stock Profit Is Tesla’s Valuation a Bubble or Backed by Real Growth? What Are Trending Stocks? Trending Stocks Explained Trucking Stocks Led the Pack Last Week: Can They Keep Rolling? Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter ..
